KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 shares of the specialty pharmaceutical company’s stock after buying an additional 54,257 shares during the period. Barclays PLC’s holdings in KalVista Pharmaceuticals were worth $778,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of KALV. China Universal Asset Management Co. Ltd. boosted its position in KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock worth $96,000 after purchasing an additional 3,328 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $126,000. SG Americas Securities LLC purchased a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at approximately $153,000. Quest Partners LLC acquired a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at $175,000. Finally, Evoke Wealth LLC purchased a new stake in KalVista Pharmaceuticals in the 2nd quarter worth $181,000.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Bank of America assumed coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective on the stock. TD Cowen started coverage on shares of KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Needham & Company LLC restated a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Thursday, December 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Buy” and a consensus price target of $25.00.

KalVista Pharmaceuticals Trading Up 6.2 %

Shares of NASDAQ KALV opened at $7.86 on Thursday. The stock has a market cap of $388.43 million, a PE ratio of -2.16 and a beta of 0.86. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.88. The company has a 50-day moving average of $9.25 and a 200 day moving average of $11.23.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,627 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $9.75, for a total transaction of $74,363.25. Following the completion of the sale, the chief executive officer now directly owns 274,596 shares in the company, valued at approximately $2,677,311. This trade represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul K. Audhya sold 8,077 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,291 shares of company stock worth $304,086 in the last ninety days. Insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).